^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    YK0901

    i
    Other names: YK0901
    Associations

    News

    Trials
    Company:
    Yingkai Saiwei Biotech
    Drug class:
    TCR modulator, KRAS G12V inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=11, Not yet recruiting, Peking University
    New P1 trial • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS G12V • KRAS G12
    |
    cyclophosphamide • oxaliplatin • YK0901